Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > insider buying continues ...

<< Previous

Bullboard Posts

Next >>

Post by MrMugsyon Nov 08, 2021 8:28am

539 Views

Post# 34098851

insider buying continues ...

Filed 2021-11-07 18:59 Tx date 2021-11-03	$ATE Antibe Therapeutics Inc.	Macnee, Walter Minnes 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$24,385 +25,000 vol $0.98 each	447,027
Older filings
Filed 2021-11-03 16:59 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$23,265 +23,500 vol $0.99 each	279,333
Filed 2021-11-03 16:58 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$3,430 +3,500 vol $0.98 each	255,833
Filed 2021-11-03 16:58 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$960.00 +1,000 vol $0.96 each	252,333
Filed 2021-11-03 16:57 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$6,175 +6,500 vol $0.95 each	251,333
Filed 2021-11-03 16:56 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$19,740 +21,000 vol $0.94 each	244,833
Filed 2021-11-03 16:55 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$4,650 +5,000 vol $0.93 each	223,833
Filed 2021-11-03 16:55 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$2,275 +2,500 vol $0.91 each	218,833
Filed 2021-11-03 16:54 Tx date 2021-11-01	$ATE Antibe Therapeutics Inc.	Wu, Yung Cheng 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$22,250 +25,000 vol $0.89 each	216,333